Jupiter Neurosciences, Inc. Presentation at the Emerging Growth Conference

Jupiter Neurosciences presents a corporate update detailing their clinical progress and licensing agreements for central nervous system and mental health therapeutics. The company has initiated patient enrollment for its Phase 2a trial evaluating JOTROL, a proprietary resveratrol formulation designed for Parkinson's disease, with readout expected in early 2027. In addition to their core pipeline, Jupiter Neurosciences has executed a term sheet with Pharmala to in-license ALA-002, an MDMA-based drug candidate targeting social anxiety disorder and PTSD. This novel formulation aims to significantly lower cardiovascular risk, hyperthermia, and abuse liability compared to racemic MDMA. Key licensing terms include an estimated total deal value of $100 million structured with modest upfront costs and milestone-based payments. The presentation also highlights how JOTROL addresses past resveratrol bioavailability limitations to achieve therapeutic blood levels without severe gastrointestinal side effects.